Published

A Single Administration of Psilocybin Persistently Rescues Cognitive Deficits Caused by Adolescent Chronic Restraint Stress Without Long-Term Changes in Synaptic Protein Gene Expression in a Rat Experimental System with Translational Relevance to Depression.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Psychedelic medicine (New Rochelle, N.Y.)
Date: 2023-03-01
Source: PubMed
DOI: 10.1089/psymed.2022.0012
PubMed: 40047006

Authors

Hibicke M Kramer HM Nichols CD

Watch author

Derived topics and classifications

psilocybin Depression Neuroplasticity Mechanism of Action Receptor Pharmacology Clinical Trial Animal Study Adolescents Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 3 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats2026-07-01 Daily Administration of Psilocin Mucate (L-130) Produces a Favorable Safety Profile and Anxiolytic Effects in Rodents Exposed to Chronic Unpredictable Mild Stress2026-01-02 A Single Administration of Psilocybin Persistently Rescues Cognitive Deficits Caused by Adolescent Chronic Restraint Stress Without Long-Term Changes in Synaptic Protein Gene Expression in a Rat Experimental System with Translational Relevance to Depression.2023-03-01

Related papers

The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young AdultsClinicalTrials.gov · 2026-08-14 Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10 Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)ClinicalTrials.gov · 2026-07-30 A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe AnxietyClinicalTrials.gov · 2026-07-23 Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled TrialClinicalTrials.gov · 2026-07-14 PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10 PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialClinicalTrials.gov · 2026-07-10 A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)ClinicalTrials.gov · 2026-06-25